
The FDA has approved the first pill, Zurzuvae, designed to treat severe postpartum depression in the US. Developed by Sage Therapeutics, the pill is taken once a day for 14 days, providing a new oral treatment option for new mothers struggling with extreme feelings. Postpartum depression affects around 400,000 people annually, and standard treatments like counseling or antidepressants may take weeks to work. The pill's approval is based on two studies that revealed fewer depression signs in those taking Zurzuvae compared to a placebo. The pill is part of a new class of neurosteroid medications with milder side effects than the IV version.
Like
Save
Share